Why the study?
This study aimed to develop and validate a nomogram utilizing the TyG index alongside readily available clinical data to predict the prognosis of STEMI patients undergoing primary PCI.
Can a nomogram incorporating the TyG index accurately predict MACE risk in STEMI patients undergoing primary PCI?
Population
1022 STEMI patients undergoing primary PCI (training n = 715, validation n = 307)
Design
Retrospective cohort study
Key result
A novel nomogram integrating the TyG index with clinical markers demonstrated strong discrimination for predicting MACE in STEMI patients after primary PCI (validation C-index 0.80; 95% CI 0.76-0.83).
Authors
Loading...
May support MACE risk stratification in STEMI post-PCI; leaves open clinical adoption pending prospective validation.
Cohort (n=1,022)
Can a nomogram incorporating the TyG index accurately predict MACE risk in STEMI patients undergoing primary PCI?
Effect estimate: C-index 0.80 (95% CI 0.76-0.83)
A novel nomogram incorporating the TyG index, hsCRP, rSS, VDn, and BNP provides accurate risk stratification for MACE in STEMI patients following primary PCI.
Huang et al. (2026) conducted a cohort in ST-elevation myocardial infarction (STEMI) (n=1,022). Triglyceride-glucose (TyG) index-based nomogram was evaluated on Model discrimination for major adverse cardiovascular events (MACE) (C-index 0.80, 95% CI 0.76-0.83). A novel nomogram integrating the TyG index with clinical markers demonstrated strong discrimination for predicting MACE in STEMI patients after primary PCI (validation C-index 0.80; 95% CI 0.76-0.83).